Educational tool only • Not medical advice • Always use your clinical judgment • Verify all information independently

This brief is 100% free to read. No login required.

Evidence verified against 2024-2025 systematic reviews

StrokeModerate evidenceSystematic Review / RCT / Meta-Analysis

Transcranial Direct Current Stimulation (tDCS) for Post-Stroke Motor Recovery: A Look at the Evidence

Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique explored as an adjunct to physical therapy for stroke recovery. While some studies suggest benefits in motor function, recent large-scale trials have not shown significant advantages over conventional therapy alone, highlighting the need for further research into optimal dosing and patient selection.

Research: July 2025

Related Videos

At-Home Exercise and tDCS for MS Rehabilitation

Trans-Cranial Direct Current Stimulation (tDCS) Explained

Key Findings

  • 1A 2025 meta-analysis showed tDCS with CIMT improved upper limb impairment and perceived motor activity.
  • 2A large 2025 RCT (TRANSPORT2) found no significant added benefit of tDCS (2mA or 4mA) when combined with mCIMT.
  • 3tDCS is generally considered safe and well-tolerated in the post-stroke population.
  • 4The effectiveness of tDCS may be influenced by factors like dosage, timing, and the specific rehabilitation protocol.
  • 5Current evidence is conflicting, and more research is needed to determine optimal parameters for tDCS in stroke rehabilitation.
For clinicians working with stroke survivors, the quest for effective neurorehabilitation strategies is ongoing. Transcranial direct current stimulation (tDCS) has emerged as a promising, non-invasive technique to enhance motor recovery when combined with physical therapy. The idea is to modulate cortical excitability to promote neuroplasticity. A typical protocol involves placing two electrodes on the scalp, with the anodal electrode over the motor cortex of the affected hemisphere to increase excitability, and the cathodal electrode over the contralesional hemisphere to decrease its inhibitory influence. A low-amplitude direct current, usually 1-2 mA, is then applied for 20-30 minutes during or immediately before a therapy session. A 2025 systematic review and meta-analysis published in *NeuroRehabilitation* found that tDCS combined with constraint-induced movement therapy (CIMT) yielded statistically significant improvements in upper limb impairment (as measured by the Fugl-Meyer Assessment) and the perceived amount of motor activity in daily life. However, it is crucial to note that a large, multicenter, randomized controlled trial (TRANSPORT2) published in *The Lancet Neurology* in 2025 did not find a significant difference in motor recovery between patients receiving tDCS (at 2mA or 4mA) and those receiving sham stimulation when combined with modified CIMT. The TRANSPORT2 trial, a phase 2 study, concluded that while tDCS is safe and feasible, it did not add significant benefit to a robust therapy program for patients 1-6 months post-stroke. This discrepancy in findings suggests that the effectiveness of tDCS may depend on a variety of factors, including the specific therapy it is paired with, the dosage, and the characteristics of the patient population. The evidence, therefore, remains mixed, and while tDCS is a tool with potential, it is not yet a guaranteed game-changer.

Clinician's Note

From my perspective, the jury is still out on tDCS. While the meta-analysis offers a glimmer of hope, the large, well-conducted TRANSPORT2 trial gives me pause. It seems that the quality and intensity of the therapy itself might be the primary driver of recovery, with tDCS having a marginal, if any, additional effect. I would be cautious about presenting tDCS as a breakthrough, but for the right patient who understands the current state of the evidence, it could be a safe, adjunctive modality to try.

Clinic Action Plan

1. Patient Selection: Consider tDCS for patients with moderate upper extremity weakness who are motivated to engage in intensive therapy. 2. Informed Consent: Discuss the mixed evidence with patients, explaining that while some studies show benefit, others do not, and that it is not a guaranteed cure. 3. Protocol: If proceeding, a common protocol is 2mA of anodal tDCS over the affected hemisphere's primary motor cortex for 20-30 minutes, concurrent with motor training. 4. Combined Therapy: Ensure tDCS is always an adjunct to an evidence-based, intensive physical or occupational therapy program like CIMT or mCIMT. 5. Outcome Measurement: Use standardized outcome measures (e.g., Fugl-Meyer, Wolf Motor Function Test) to track progress and objectively determine if the intervention is beneficial for the individual patient.

Common Mistakes to Avoid

  • Using tDCS as a standalone treatment without intensive, concurrent therapy.
  • Incorrect electrode placement, leading to stimulation of non-target brain regions.
  • Inconsistent application of the tDCS protocol across sessions.
  • Over-promising the benefits of tDCS to patients and families.

Frequently Asked Questions

Premium Deep Dive

This brief includes an extended deep-dive section with clinical nuance, dosing details, edge cases, and special population considerations.

Unlock with Premium — $99/yr
GRADE-graded with DOI links Evidence verified
This brief is for educational purposes only. Always verify clinical decisions with peer-reviewed sources and your professional judgment.

Want more from NeuroDash?

Save protocols, track CEU hours, download PDFs, and get unlimited AI access.

Explore Premium — $99/yr

Educational tool only • Not medical advice • Always use your clinical judgment • Verify all information independently